Convergen Raises $10M Seed to Advance TrimTAC Platform for Targeted Protein Degradation in Neurodegenerative Diseases – News
Biotech startup Convergen has closed $10 million in Seed funding to accelerate development of its TrimTAC platform, a next-generation targeted protein degradation (TPD) technology designed to selectively clear pathogenic protein aggregates. The round was led by Qiming Venture Partners, a leading global venture capital firm specializing in healthcare and life sciences. Convergen’s proprietary TrimTAC platform…
